Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15383092 | 0.92 | TDP1 (0.39) | MAPTTSHRTDP1MEN1LMNA | |
| SCHEMBL17194014 | 0.92 | MAPT (0.36) | MAPTTSHRTDP1MEN1LMNA | |
| SCHEMBL12262572 | 0.92 | MAPT (0.36) | MAPTTSHRTDP1MEN1LMNA | |
| SCHEMBL11986265 | 0.92 | TDP1 (0.39) | MAPTTSHRTDP1MEN1LMNA | |
| SCHEMBL15383093 | 0.92 | MAPT (0.38) | MAPTTSHRTDP1MAPK1HSD17B10 | |
| SCHEMBL15441005 | 0.89 | MAPT (0.39) | MAPTTSHRTDP1MAPK1HSD17B10 | |
| SCHEMBL15780104 | 0.89 | MAPT (0.41) | MAPTTSHRTDP1 | |
| SCHEMBL11986256 | 0.88 | MAPT (0.51) | MAPTTSHRTDP1ALDH1A1MEN1 | |
| SCHEMBL15180215 | 0.88 | MAPT (0.43) | MAPTTSHR | |
| SCHEMBL12262552 | 0.88 | TSHR (0.44) | MAPTTSHRTDP1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884937-B2 | Polymer compositions and methods | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2018-02-06 | — | — | US | disclosed |
| US-9834710-B2 | Adhesive compositions and methods | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2017-12-05 | — | — | US | disclosed |
| US-9738784-B2 | Polymer blends | NOVOMER, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738784-B2 | Polymer blends | NOVOMER, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170145147-A1 | HIGH STRENGTH POLYURETHANE FOAM COMPOSITIONS AND METHODS | NOVOMER, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170107241-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NOVOMER, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160319064-A1 | POLYMER COMPOSITIONS AND METHODS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2016-11-03 | — | — | US | disclosed |
| US-9403861-B2 | Salen complexes with dianionic counterions | NOVOMER, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150344751-A1 | ADHESIVE COMPOSITIONS AND METHODS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2015-12-03 | — | — | US | disclosed |
| US-20150083326-A1 | ADHESIVE COMPOSITIONS AND METHODS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2015-03-26 | — | — | US | disclosed |
| US-20140336354-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2014-11-13 | — | — | US | disclosed |
| US-8748555-B2 | Structurally precise poly(propylene carbonate) compositions | NOVOMER, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130209775-A1 | POLYMER BLENDS | NOVOMER, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130209775-A1 | POLYMER BLENDS | NOVOMER, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20120156410-A1 | STRUCTURALLY PRECISE POLY(PROPYLENE CARBONATE) COMPOSITIONS | NOVOMER, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107241-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NCLN, POLN, NCL | MAPT 1373/4885TSHR 4704/4885TDP1 3455/4885 |
| US-20140336354-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NCLN, POLN, NCL | MAPT 1373/4885TSHR 4704/4885TDP1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.